1. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol. 2002; 9. 138(9):1149–1155. PMID:
12224975.
2. Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg. 1999; 3. 25(3):224–232. PMID:
10193972.
Article
3. Chowdri NA, Masarat M, Mattoo A, Darzi MA. Keloids and hypertrophic scars: results with intraoperative and serial postoperative corticosteroid injection therapy. Aust N Z J Surg. 1999; 9. 69(9):655–659. PMID:
10515339.
Article
4. Alster T. Laser scar revision: comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol Surg. 2003; 1. 29(1):25–29. PMID:
12534508.
Article
5. Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev. 1976; 9. 3(3):121–139. PMID:
786455.
Article
6. Miyamura S, Shigeno N, Matsui M, Wakaki S, Uzu K. The biological studies on mitomycin I: antibacterial activities of mitomycin derivatives. J Antibiot (Tokyo). 1967; 3. 20(2):72–76. PMID:
4964076.
7. Hu D, Sires BS, Tong DC, Royack GA, Oda D. Effect of brief exposure to mitomycin C on cultured human nasal mucosa fibroblasts. Ophthal Plast Reconstr Surg. 2000; 3. 16(2):119–125.
Article
8. Garrett CG, Soto J, Riddick J, Billante CR, Reinisch L. Effect of mitomycin-C on vocal fold healing in a canine model. Ann Otol Rhinol Laryngol. 2001; 1. 110(1):25–30. PMID:
11201804.
Article
9. De Bruijn EA, Sleeboom HP, van Helsdingen PJ, van Oosterom AT, Tjaden UR, Maes RA. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Cancer. 1992; 5. 28. 51(3):359–364. PMID:
1592527.
Article
10. Oboshi S, Matsui M, Ishii S, Masago N, Wakaki S. Antitumor studies on mitomycin derivatives. II. Effec of solid tumor of sarcoma-180. Gann. 1967; 8. 58(4):315–321. PMID:
6079789.
11. Hueman EM, Simpson CB. Airway complications from topical mitomycin C. Otolaryngol Head Neck Surg. 2005; 12. 133(6):831–835. PMID:
16360498.
Article
12. Sherris DA, Larrabee WF Jr, Murakami CS. Management of scar contractures, hypertrophic scars, and keloids. Otolaryngol Clin North Am. 1995; 10. 28(5):1057–1068. PMID:
8559572.
Article
13. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope. 2001; 2. 111(2):218–226. PMID:
11210864.
Article
14. Keir J. Botulinum toxin-physiology and applications in head and neck disorders. Head Neck. 2005; 6. 27(6):525–535. PMID:
15898076.
Article
15. Gassner HG, Sherris DA. Chemoimmobilization: improving predictability in the treatment of facial scars. Plast Reconstr Surg. 2003; 10. 112(5):1464–1466. PMID:
14504533.
Article
16. Kantor J, Margolis DJ. Efficacy and prognostic value of simple wound measurements. Arch Dermatol. 1998; 12. 134(12):1571–1574. PMID:
9875195.
Article
17. Philips LG. Townsend CM, Beauchamp RD, Evers BM, Mattox KL, editors. Wound healing. Textbook of surgery. 2001. 16th ed. Philadelphia (PA): WB Saunders Co.;p. 131–155.
18. Ribeiro Fde A, Guaraldo L, Borges Jde P, Zacchi FF, Eckley CA. Clinical and histological healing of surgical wounds treated with mitomycin C. Laryngoscope. 2004; 1. 114(1):148–152. PMID:
14710012.
Article
19. Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg. 2000; 5. 105(6):1948–1953. PMID:
10839391.
Article
20. Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006; 8. 81(8):1023–1028. PMID:
16901024.
Article
21. Khera M, Boone TB, Smith CP. Botulinum toxin type A: a novel approach to the treatment of recurrent urethral strictures. J Urol. 2004; 8. 172(2):574–575. PMID:
15247734.
Article